These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28781275)

  • 1. [Reprogramming technology reveals genetic and functional diversity of subclones in myelodysplastic syndromes].
    Chonabayashi K; Yoshida Y; Takaori-Kondo A
    Rinsho Ketsueki; 2017; 58(7):787-791. PubMed ID: 28781275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes.
    Stankov K; Stankov S; Katanic J
    Curr Pharm Des; 2017; 23(1):135-169. PubMed ID: 27697023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
    Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia.
    Kotini AG; Chang CJ; Chow A; Yuan H; Ho TC; Wang T; Vora S; Solovyov A; Husser C; Olszewska M; Teruya-Feldstein J; Perumal D; Klimek VM; Spyridonidis A; Rampal RK; Silverman L; Reddy EP; Papaemmanuil E; Parekh S; Greenbaum BD; Leslie CS; Kharas MG; Papapetrou EP
    Cell Stem Cell; 2017 Mar; 20(3):315-328.e7. PubMed ID: 28215825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pathophysiology of MDS: genomic aberrations].
    Ichikawa M
    Rinsho Ketsueki; 2016; 57(10):1972-1979. PubMed ID: 27725595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.
    Bernasconi P
    Br J Haematol; 2008 Sep; 142(5):695-708. PubMed ID: 18540941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes.
    Hsu J; Reilly A; Hayes BJ; Clough CA; Konnick EQ; Torok-Storb B; Gulsuner S; Wu D; Becker PS; Keel SB; Abkowitz JL; Doulatov S
    Blood; 2019 Jul; 134(2):186-198. PubMed ID: 31010849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level.
    Chen J; Kao YR; Sun D; Todorova TI; Reynolds D; Narayanagari SR; Montagna C; Will B; Verma A; Steidl U
    Nat Med; 2019 Jan; 25(1):103-110. PubMed ID: 30510255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Application of iPS cells derived from congenital myelodysplastic syndrome for research of nomal hematopoesis and hematological malignancies].
    Nakajima H
    Rinsho Ketsueki; 2016 Aug; 57(8):1087-94. PubMed ID: 27599428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant hematopoietic cell lines: in vitro models for the study of myelodysplastic syndromes.
    Drexler HG
    Leuk Res; 2000 Feb; 24(2):109-15. PubMed ID: 10654445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
    Nakajima H
    Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndromes: the pediatric point of view.
    Locatelli F; Zecca M; Pession A; Maserati E; De Stefano P; Severi F
    Haematologica; 1995; 80(3):268-79. PubMed ID: 7672722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From MDS/AML to iPSC and back again.
    Jonas BA
    Sci Transl Med; 2017 Mar; 9(380):. PubMed ID: 28275157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies.
    Tatwavedi D; Pellagatti A; Boultwood J
    Adv Biol Regul; 2024 Jan; 91():100993. PubMed ID: 37827894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelodysplastic syndrome hematopoietic stem cell.
    Li J
    Int J Cancer; 2013 Aug; 133(3):525-33. PubMed ID: 23047726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow niche in the myelodysplastic syndromes.
    Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
    Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studying clonal evolution of myeloid malignancies using induced pluripotent stem cells.
    Doulatov S; Papapetrou EP
    Curr Opin Hematol; 2021 Jan; 28(1):50-56. PubMed ID: 33264225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bridging the Gaps: iPSC-Based Models from CHIP to MDS to AML.
    Bernt KM
    Cell Stem Cell; 2017 Mar; 20(3):298-299. PubMed ID: 28257709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Senescent Mesenchymal Stem Cells Contribute to Progression of Myelodysplastic Syndromes-Review].
    Pang YB; Li WW; Luo JM; Ji J; DU X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):942-946. PubMed ID: 29950248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.
    Kennedy JA; Ebert BL
    J Clin Oncol; 2017 Mar; 35(9):968-974. PubMed ID: 28297619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.